Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 20/20 | 0.73 |
| ▸ | HCRTR2 | O43614 | 20/20 | 0.73 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.53 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4317077 | 0.86 | HCRTR1 (0.73) | HCRTR1HCRTR2NR1I2ADRA2BKCNH2 | |
| SCHEMBL18910853 | 0.85 | HCRTR2 (1.00) | HCRTR1HCRTR2 | |
| SCHEMBL14843743 | 0.83 | HCRTR2 (0.83) | HCRTR1HCRTR2 | |
| SCHEMBL2863201 | 0.83 | HCRTR1 (0.68) | HCRTR1HCRTR2NR1I2ADRA2BKCNH2 | |
| SCHEMBL13789967 | 0.81 | HCRTR1 (0.77) | HCRTR1HCRTR2NR1I2ADRA2BKCNH2 | |
| SCHEMBL2903857 | 0.81 | HCRTR1 (0.77) | HCRTR1HCRTR2NR1I2ADRA2BKCNH2 | |
| SCHEMBL2904613 | 0.81 | HCRTR1 (0.68) | HCRTR1HCRTR2NR1I2ADRA2BKCNH2 | |
| SCHEMBL8218307 | 0.81 | HCRTR1 (0.68) | HCRTR1HCRTR2NR1I2ADRA2BKCNH2 | |
| SCHEMBL4310626 | 0.81 | HCRTR1 (0.68) | HCRTR1HCRTR2NR1I2ADRA2BKCNH2 | |
| SCHEMBL2898491 | 0.81 | HCRTR1 (0.77) | HCRTR1HCRTR2NR1I2ADRA2BKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2001485-B1 | DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2015-09-09 | — | — | EP | disclosed |
| US-20090124603-A1 | Diazepan Orexin Receptor Antagonists | MERCK SHARP & DOHME LLC | 2009-05-14 | — | — | US | disclosed |
| US-20090124603-A1 | Diazepan Orexin Receptor Antagonists | MERCK SHARP & DOHME LLC | 2009-05-14 | — | — | US | disclosed |
| WO-2007126935-A2 | DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124603-A1 | Diazepan Orexin Receptor Antagonists | HCRTR2, HCRTR1, OXTR | HCRTR1 2/4885HCRTR2 1/4885NR1I2 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.